Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia

Kurt M., Shorbagi A., Altundag K., Elkiran T., Gullu I., Kansu E.

AMERICAN JOURNAL OF HEMATOLOGY, cilt.80, sa.3, ss.213-215, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 80 Sayı: 3
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1002/ajh.20432
  • Dergi Adı: AMERICAN JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.213-215
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Gemtuzumab ozogamicin (GO; CMA-676; Mylotarg((TM))) is a chemotherapeutic agent approved for the treatment of CD33-positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno-occlusive disease has been reported to develop as a late complication of gemtuzumab ozogamicin treatment. A patient who developed Budd-Chiari Syndrome with hepatic vein thrombosis following treatment with GO is presented. This complication has not been previously reported, and it deserves to be considered as a possible adverse effect of gemtuzumab ozogamicin.